An NCI-designated Consortium Cancer Center
|
|
|
Weekly Research Newsletter
|
|
|
Moores Cancer Center (MCC) Shared Resources Survey
All MCC members are invited to participate in an important survey concerning our Shared Resources. The survey data collected will inform the Cancer Center Support Grant (CCSG) renewal. Please make your voice heard. We need to hear from YOU!
|
|
|
Join the Work in Progress Seminar Series
Please join MCC's standing Work in Progress Seminar Series every first Wednesday of the month. If you are interested in presenting or joining, then please contact Program Coordinator, Diana Arroyo at d1arroyo@health.ucsd.edu.
|
|
|
Highlights from The Cancer Letter |
What Ruben Mesa Is Thinking as He Steps into One of the Most Watched Jobs in Cancer
Read full article on page 6 of The Cancer Letter, volume 49 number 41.
Medicaid Expansion Improves Cancer Survival Outcomes for Young Adults, Winship Study Finds
Read full article on page 26 of The Cancer Letter, volume 49 number 1.
|
|
|
|
Pharmacology Seminar Series
Unique Scaffolds for Localized cAMP Signaling in Heart
Tuesday, January 17, 2023 (IN PERSON) at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
9500 Gilman Drive, La Jolla, CA 92037
Optional Webinar Registration
Carmen W. Dessauer, Ph.D.
Professor and Chair ad interim
Department of Integrative Biology and Pharmacology
UTHealth at Houston, McGovern Medical School
Hosted by Susan Taylor, Ph.D.
|
|
|
|
DRM Seminar Series
Publishing with Cell Press: Inside the Editorial Process
Friday, January 20, 2023 from 2:00 p.m. to 3:00 p.m. PT
Sanford Consortium for Regenerative Medicine
Conference Room 1013 A/B
2880 Torrey Pines Scenic Drive, La Jolla, CA 92037
Zoom Link Available Upon Request
Sheila Chari, Ph.D.
Editor-in-Chief, Cell Stem Cell
Executive Editor, Cell Press
Hosted by Catriona Jamieson, M.D., Ph.D.
Contact: drmseminarseries@ucsd.edu
|
|
|
| Pharmacology Seminar Series
Inner Workings of the Inflammasome Engine
Tuesday, January 24, 2023 (IN PERSON) at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
9500 Gilman Drive, La Jolla, CA 92037
Optional Webinar Registration
Hao Wu, Ph.D.
Asa and Patricia Springer Professor
Department of Biological Chemistry and Molecular Pharmacology
Harvard Medical School and Boston Children's Hospital
Hosted by Susan Taylor, Ph.D.
|
|
|
| DRM Seminar Series
APOBEC3 Enzymes: From Retroviral Restriction Factors to Cancer Drivers . . . and Beyond?
Wednesday, January 25, 2023 from 3:00 to 4:00 p.m. PT
Sanford Consortium for Regenerative Medicine
Conference Room 1013 A/B
2880 Torrey Pines Scenic Drive, La Jolla, CA 92037
Zoom Link Available Upon Request
Tim Fenton, Ph.D.
Associate Professor, Cancer Biology
Faculty of Medicine
School of Cancer Sciences/Centre for Cancer Immunology
University of Southampton
Hosted by Frank Furnari, Ph.D.
Contact: drmseminarseries@ucsd.edu
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
|
|
2023 Cervical Cancer Awareness Summit
Thursday, January 19, 2023 from 10:00 a.m. to 12:00 p.m. PT
Join us virtually to learn from leaders in the field on the current and future state of cervical cancer treatment, research, and prevention.
|
| |
San Diego Colorectal Cancer Screening Roundtable
Thursday, February 22, 2023 from 10:00 a.m. to 12:00 p.m.
Join us for information on the current state of colorectal cancer screening in San Diego, upcoming changes in Medi-Cal, emerging screening tests, and how we can increase screening to get back on track.
This roundtable is designed for medical directors, clinicians, quality improvement staff, panel managers, project managers, and health center staff to hear and share best practices on improving colorectal cancer screenings in San Diego County.
|
|
|
Student Volunteers Available
MCC Cancer Research, Training, and Education Coordination (CRTEC) has identified three motivated undergraduate students who are interested in volunteering in a lab at MCC. This is a win-win research experience for the students and your lab. Please contact Amy Spilkin, Ph.D. at aspilkin@health.ucsd.edu, if you would like to connect with one or more of these students:
|
- Third-year UCSD undergraduate majoring in Biology, minoring in Math
- Second-year UCSD premed undergraduate majoring in Human Biology
-
First-year UCSD undergraduate majoring in Cognitive and Behavioral Neuroscience
|
CRTEC administration will complete all necessary paperwork for these student volunteers.
|
|
|
Speed Mentoring Workshop, Faculty Sign Ups
Faculty Members of MCC are invited to serve a mentors at the MCC Speed Mentoring Workshops, organized by MCC CRTEC. These workshops serve not only undergraduate, graduate, and post-graduate students, but also project scientists, research scientists, and junior faculty. Please select the session(s) for which are are available to mentor, and please select all that apply. You will be scheduled for only one of the dates that you choose—providing several dates merely helps to coordinate schedules. You will be contacted with a confirmation of the schedule.
CRTEC Speed Mentoring takes place on the second Thursday of each month from 12:00 p.m. to 1:00 p.m. on Zoom. Participating faculty members will receive 1 hour of mentorship credit, approved by MCC leadership.
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITIES
|
|
|
Faculty Seed Grant Proposals for 2023-2024 Award Year
Maximum funding $75,000 for 2023-2024
The University of California (UC) Cancer Research Coordinating Committee (CRCC) is a systemwide, faculty-directed cancer research program that provides competitive intramural research awards for topics in any discipline that address any aspect of cancer, which include its origins, detection, prevention, and cure. The UC CRCC provides 1-year seed grants to faculty on the 10 UC campuses, with the expectation that the most promising endeavors will become competitive for larger, long-term grants from other funding sources. Awards are made in two categories: New Assistant Professor (NAP) and Regular (REG).
Required LOI Deadline: January 24, 2023
Application Deadline: April 13, 2023
|
| |
Advancing Head and Neck Cancer Early Detection (AHEAD) Research
Maximum funding $500,000 direct costs/year for 5 years
The purpose of this funding opportunity announcement (FOA) is to accelerate translation of research to improve early detection of head and neck cancers (HNC). This FOA seeks applications that target early detection of HNC by (1) applying molecular, cellular, and multi-omics signatures to clinical studies for differentiating benign from premalignant lesions and (2) identifying prognostic signatures on the transformation from premalignant to malignant lesions.
Deadline: January 27, 2023 at 5:00 p.m.
|
|
|
The UC Pancreatic Cancer Consortium Plans to Submit a SPORE Proposal to the National Cancer Institute (NCI) in May, 2023
As you may know, SPORE project proposals are distinctly different from either R01 or U01 research mechanisms, in that the proposed projects must be translational. In every SPORE project, the development of new cancer-relevant interventions should include both a laboratory component and a human application (see RFP linked below for further detail). Project budgets are expected on the order of $200,000–$250,000/year for 5 years, although projects on early detection, prevention, or population science can request up to an additional $120,000/year.
Deadline: Tuesday, January 31, 2023
Questions? Contact Kurt Giles, D.Phil. at kurt.giles@ucsf.edu
|
|
|
Prostate Cancer Foundation 2023 Young Investigator Awards Request for Letters of Intent/Full Applications
Award: $75,000 per year for 3 years
The award funds may be used innovatively and flexibly to advance the career and research efforts of the awardee. This for example, includes funding "protected time" or direct costs for laboratory science. This award does not support indirect costs such as institutional overhead. Every PCF Young Investigator is required to be under the direct supervision of 1-3 mentors. Young Investigator awardees are required to attend the Annual PCF Scientific Retreat and Young Investigator Forum, typically held in October, throughout the duration of their award.
LOI Deadline: February 10, 2023 by 3:00 p.m. ET
Submission Portal Opens: Monday, February 27, 2023
Invited Full Application Deadline: Monday, April 24, 2023 by 3:00 p.m. ET
Questions? Contact LettersofIntent@pcf.org.
|
|
|
Pragmatic Trials across the Cancer Control Continuum (UG3/UH3 Clinical Trial Required)
Application budgets may not exceed $500,000 in direct costs per year for the UG3 phase and may not exceed $750,000 in direct costs per year for the UH3 phase
Through this Funding Opportunity Announcement (FOA), the NCI intends to accelerate the development of evidence-based cancer-related interventions that reflect the diversity of people, places, contexts, and settings in the United States. Specifically, this FOA will support research that tests the impact of cancer-related interventions on cancer-related outcomes across the cancer control continuum using a pragmatic trial study design. This FOA will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support refining the cancer-related intervention and finalizing study-related activities in preparation for conducting the pragmatic trial during the UH3 phase.
Deadline: February 14, 2023 by 5:00 p.m. and June 14, 2023 by 5:00 p.m.
|
|
|
2023 ACTRI Pilot Projects: Community Research Partnership
These UCSD, Altman Clinical and Translational Research Institute (ACTRI) grants are (1) 1-year competitive awards (up to $30,000) to provide funding for early-stage projects and (2) available to all ACTRI members with faculty appointments; funding priority is given to early-career faculty.
Requests for assistance with identifying potential community or academic partners should be made between October 2022 and November 2022.
Deadline: Friday, February 24, 2023 by 2:00 p.m. PT
|
|
|
University of California, Hematologic Malignancies Consortium (UCHMC) Request for Proposals (RFP)
The UCHMC is requesting submission of proposals within two potential areas of funding: RFP A and RFP B.
All applications are to be submitted via email as a single PDF to Jesika Reiner, M.P.H., M.B.A. at JReiner@uchmc.org and Mwieduwilt@uchmc.org.
RFP A: UCHMC Funds for Junior Faculty and Trainee Competitive Seed Grants
This funding will support single or multi-center pilot clinical trials, translational lab-based projects, or retrospective projects, which may ultimately grow into multi-center UCHMC interventional clinical trials. Funding may be applied for fellowship support to conduct clinical trials research with the UCHMC. Funding also may support correlative research that may or may not be associated with an existing UCHMC trial yet with translational aims that possess potential for development into a UCHMC trial. The award amount will be determined by the UCHMC Steering Committee, but individual requests should not exceed $40,000.
RFP B: UCHMC Funds for Clinical Trials Support
This funding will support underfunded yet promising clinical trials and correlative research projects associated with an existing clinical trials or other multi-center projects that hold promise for development into larger multicenter UCHMC clinical trials. These awards will range from $100,000 to $150,000 in a given award period, with the number of projects awarded based on number of applications and scientific need as determined by the UCHMC Steering Committee, which reserves the right to award a larger total funds as it see fit.
Applicants may apply for both RFPs but will be awarded only one as a lead investigator. An applicant can be a collaborator on more than one application in a given award period.
Application Format
|
- Cover Page
- Project title
- Project investigators (Lead and Sub-Investigators) and affiliations
- Project start date
- Project end date
- Concurrent UCHMC applications of Lead Investigator
- Applicant contact
- Project Information
- Brief project description with hypothesis(es)
- Detailed project description with supporting preclinical and/or clinical data, rationale, study design, and statistical plan, as appropriate
- Budget
- Budget justification
- Other sources of funding
-
Statement of commitment to develop results into UCHMC interventional clinical trials when possible
- Attachments
- CVs of investigators associated with the proposed project
|
|
|
Call for Applications to Fund Travel to Scholarly Meeting for FY 2022/23, Co-infection and Cancer (R01 and R21 Clinical Trial Not Allowed)
Applications may be submitted throughout the year but must be received and approved prior to the conference start date. Applications will be reviewed while funds are available. Funds will not be awarded retroactively.
Any UCSD Health Sciences (HS) Clinical series faculty member holding an M.D. or D.O. can receive one trip every other fiscal year (July 1-June 30). Travel awards (domestic or foreign) will be made for a maximum of $750 toward standard economy airfare and/or registration fees (documentation required).
Eligibility is to HS Clinical series faculty who (1) have an accepted abstract to a scientific professional society conference, (2) are not a member of the Academic Senate, and (3) are either the first or senior author on the abstract podium or poster presentation of original clinical research. Invited lectures, workshops, or panel or moderator invites are ineligible and will not be considered.
|
|
|
Co-infection and Cancer (R01 and R21 Clinical Trial Not Allowed)
R01 Award: Maximum duration is 5 years. For over $500,000/year in direct costs, NIH approval is required.
R21 Award: Combined budget for direct costs for the 2-year maximum project period may not exceed $275,000. No more than $200,000 may be requested in any single year.
The purpose of this FOA is to enhance mechanistic and epidemiologic investigations that address the roles of co-infection and cancer to illuminate presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents—either concurrently or sequentially—and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and co-infections that engender novel opportunities for prevention and treatment.
Deadline: NIH standard submission dates apply.
|
|
|
NCI Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
Award: Application budgets are not limited yet must reflect the actual needs of the proposed project. The project period may not exceed 5 years.
The purpose of this FOA is to enhance mechanistic and epidemiologic investigations that address the roles of co-infection and cancer to illuminate presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents—either concurrently or sequentially—and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and co-infections that engender novel opportunities for prevention and treatment.
Deadline: NIH standard submission dates apply.
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
NCI Cancer Screening Research Network: Coordinating and Communication Center (CCC) (UG1 Clinical Trial Required)
NCI intends to commit $1.5M in FY 2024 to fund one award; $2M is expected to be allocated per year in subsequent years for the CCC; maximum project period is 4 years.
LOI Deadline: January 28, 2023
Application Deadline: February 28, 2023
|
|
|
NCI Cancer Screening Research Network: Statistics and Data Management Center (SDMC) (UG1 Clinical Trial Required)
NCI intends to commit $1M in FY 2024 to fund one award; $2M is expected to be allocated to per year in subsequent years for the SDMC; maximum project period is 4 years.
LOI Deadline: January 28, 2023
Application Deadline: February 28, 2023
|
|
|
NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub (UG1 Clinical Trial Required)
NCI intends to commit $8M in FY 2024 to fund 10-15 awards. $9M is expected to be allocated per year in subsequent years for ACCESS Hub; requested budget must not exceed $750,000 in direct costs per year; maximum project period is 4 years.
LOI Deadline: January 28, 2023
Application Deadline: February 28, 2023
|
| Damon Runyon, Clinical Investigator Award
Award: $600,000 award for 3 years, distributed as $200,000 per year.
Deadline: February 1, 2023 at 4:00 p.m. ET
|
|
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
Maximum budget $375,000 direct costs/year for 5 years; NIH R01 standard due dates apply.
Deadline: February 5, 2023 at 5:00 p.m.
|
|
|
Coordinating Center for Cannabis and Cannabinoid Use Among Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U24 Clinical Trial Not Allowed)
$500,000 direct costs per year; maximum project period is 5 years.
Deadline: February 17, 2023 at 5:00 p.m. PT
|
|
Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed)
$500,000 direct costs per year; maximum project period is 5 years.
Deadline: February 18, 2023 at 5:00 p.m. PT
|
|
Notice of Special Interest (NOSI): Administrative Supplement for NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
One CAP-IT Data and Resource Coordination Center will be awarded with a maximum total cost of $800,000 per year (maximum direct cost is $480,000 per year) in fiscal year 2023; at least 1 full year on the parent grant must remain at the time of funding; application budget is limited to 4 years.
Deadline: February 28, 2023
|
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, U2C Clinical Trial Optional)
Application budgets may not exceed $150,000 in direct costs per year.
Deadline: March 1, 2023 and September 1, 2023
|
| NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
A budget for direct costs of up to $50,000 per year may be requested; maximum project period is 2 years.
Deadline: Standard NIH deadlines apply
|
|
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
The combined budget for direct costs for the 2-year maximum project period may not exceed $275,000; no more than $200,000 may be requested in any single year.
Deadline: Standard NIH deadlines apply
|
|
|
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Application budgets are not limited but must reflect the actual needs of the proposed project; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
| Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Budgets are limited to $600,000 direct costs (excluding consortium F&A) per year; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
| |
|
POSTDOCTORAL FUNDING OPPORTUNITIES
|
|
|
Cancer Therapeutics Training (CT2) Program at MCC: OPEN POSITIONS AVAILABLE
PIs: Michael Bouvet, M.D. and Dwayne Stupack, Ph.D.
Description: The goal of the Cancer Therapeutics Training (CT2) Program is to train the next generation of leaders in the field of cancer drug and diagnostics development. The CT2 Program is open to both M.D.s and Ph.D.s and provides an intensive 2-year period of research and training in the development of novel cancer therapeutics or diagnostics at the Moores Cancer Center. Trainees not only execute a research program under the direction of a member of the faculty of this Comprehensive Cancer Center, but also participate in coursework, seminars, and lectures. The research may be basic, translational, or clinical, yet all trainees will become versed in each major phase of the drug development process. Graduates of the program are prepared to transition to leadership roles in cancer therapeutics development in either an academic or commercial environment.
Salary/Stipend Information: NIH stipend scale
Application Procedure, Documents, and Requirements
|
-
Complete CT2 program application form (downloadable from the website below)
- Curriculum vitae
- One-page personal statement
- Proof of U.S. citizenship or permanent resident status
- Three letters of recommendation (one from an identified mentor)
- Ph.D. or M.D. degree
|
For more information or to apply, please contact Amy Spilkin, Ph.D. at aspilkin@health.ucsd.edu
See WEBSITE for more details about the CT2 program.
Deadline: January 15, 2023
|
|
|
Saturday, January 28, 2023
|
|
|
Living with Melanoma Patient Symposium
Saturday, February 4, 2023 from 8:30 a.m. to 12:00 p.m.
University of California, San Francisco, Mission Bay Campus
Arthur and Toni Rembe Rock Hall
1550 4th Street, San Francisco, CA 94158
Hosted by the AIM at Melanoma Foundation and the University of California (UC) Melanoma & Skin Cancer Consortium, this symposium will bring together five of the UC's National Cancer Institute-designated Comprehensive Cancer Centers to share research, clinical trials, and best practices.
|
|
|
Salk T32 Cancer Symposium
Friday, February 10, 2023 from 8:30 a.m. to 5:00 p.m.
Salk Institute, Conrad T. Prebys Auditorium
10010 North Torrey Pines Road
La Jolla, CA 92037
The theme of this year’s symposium is cancer therapeutics. An outstanding lineup of speakers will present on topics that include precision medicine, cancer epigenetics, and immunotherapy. The goal of the symposium is to highlight the amazing research being done by postdocs and students. Those working in cancer biology are encouraged to join attend (deadline: January 27, 2023) and to submit an abstract (deadline: January 9, 2023).
|
|
|
Kyoto University Symposium
Tuesday, February 28, 2023 from 1:00 p.m. to 5:00 p.m.
Roth Auditorium
Sanford Consortium for Regenerative Medicine
|
|
|
| Keynote Speaker
Dr. Shinya Yamanaka
Nobel Laureate in Physiology or Medicine 2012
Director Emeritus and Professor
Department of Life Science Frontiers
Center for iPS Cell Research and Application
Kyoto University
Read More
|
|
|
The symposium will be followed by a reception at the Bella Vista Cafe. Save the date and join us for this unique opportunity to reinvigorate academic collaborations with the prestigious university in Japan.
For more information, please contact Ms. Mariko Adachi, International Strategy Office, Kyoto University at osl.symposium@mail2.adm.kyoto-u.ac.jp
|
|
|
Big Data Training for Cancer Research—BigCare 2023 Summer Workshop
Friday, May 19, 2023 to Sunday, May 28, 2023
Purdue University
West Lafayette, Indiana
There is no cost for registration or tuition for this workshop, which will be held on-site at Purdue University in West Lafayette, IN. Moreover, there will be no cost for food or lodging, and travel scholarships will be available for a limited number of participants. Please visit the Purdue University Website for updates.
|
|
|
| Congratulations to Molly Klipfel for Being Recognized as Clinical Trials Office (CTO), Staff of the Month for the Month of December, 2022!
The CTO and Breast Team are recognizing Molly for being reliable, professional, dedicated, and kind. She is a team player and always approaches challenges with a positive attitude. Leading up to the FDA Audit for the Breast Team, Molly put in countless hours, preparing the charts and reviewing every detail. She showed excellent leadership skills through thoughtful delegation and creative problem solving. During the audit, she remained calm in a very stressful situation and put everyone in the room at ease. Molly is a good communicator, both with her team and her patients, and is always eager to learn something new. The Breast Team is lucky to have such an excellent coordinator! Kudos to Molly!
|
|
|
SHARED RESOURCE SPOTLIGHT
|
|
|
Biostatistics Shared Resource (BSR)
The MCC BSR not only provides comprehensive biostatistics and data analytics collaboration and support, but also is happy to help with grant and protocol development.
The BSR, established in 1995, currently comprises six faculty members and two staff biostatisticians. Together, BSR faculty and staff support best practices in data analysis and statistical inference; reproducible research; clinical trial design, reporting and analysis; causal inference from observational studies; and statistical methodology.
MCC members are not charged for BSR consulting during proposal preparation and early clinical trial protocol development. The BSR's MCC funding is intended for development of long-term collaboration that leads to not only foundation, federal, and industry funding, but also high-profile publications. The BSR also welcomes short consultation requests. Funded projects are expected to incorporate a budget for adequate biostatistics support, which often strengthens grant applications.
The BSR encourages early interaction during proposal planning. For standard proposal development, the BSR needs 4 weeks' advanced notice to review aims, methods, and preliminary results. The BSR can provide not only statistical sections, which include sample size, power calculations, and analysis methods, but also targeted biosketches and letters of support for grant proposals. The BSR recommends contacting the BSR Manager at least 8 weeks in advance for more complex multi-PI, multi-institution, multi-project proposals.
Early interaction during clinical trial development is encouraged. The BSR will provide not only sample size, power calculations, and justifications for any interim safety and/or efficacy analysis, but also randomization plans. During trial operation, the BSR can provide DSMB and regulatory reports, in addition to interim safety and/or final efficacy analysis. The BSR requires negotiated approval of trial budget prior to undertaking these activities.
Please feel free to contact the BSR, which aims to respond within 2 days with a consultation plan. Email Emily Pittman, Ph.D., BSR Manager at eipittman@health.ucsd.edu.
|
|
|
-
Peng Q, Huang Z, Sun K, Liu Y, Yoon CW, Harrison RES, Schmitt DL, Zhu L, Wu Y, Tasan I, Zhao H, Zhang J (CBS), Zhong S (SFG), Chien S, Wang Y (CBS). Engineering inducible biomolecular assemblies for genome imaging and manipulation in living cells. Nat Commun. 2022 DEC 24.
- Yang X, Xu X, Breuss MW, Antaki D, Ball LL, Chung C, Shen J, Li C, George RD, Wang Y, Bae T, Cheng Y, Abyzov A, Wei L, Alexandrov LB (SFG), Sebat JL, Gleeson JG. Control-independent mosaic single nucleotide variant detection with DeepMosaic. Nat Biotechnol. 2023 JAN 02.
-
Bryant AK, Lee KM, Alba PR, Murphy JD (CCP), Martinez ME (CCP), Natarajan L (CCP), Green MD, Dess RT, Anglin-Foote TR, Robison B, DuVall SL, Lynch JA, Rose BS. Association of prostate-specific antigen screening rates with subsequent metastatic prostate cancer incidence at US Veterans Health Administration facilities. JAMA Oncol. 2022 DEC 01.
-
Brightman SE, Naradikian MS, Thota RR, Becker A, Montero L, Bahmanof M, Premlal A, Greenbaum JA, Peters B, Cohen EE (STT), Miller AM (STT), Schoenberger SP (STT). Tumor cells fail to present MHC-II restricted epitopes derived from oncogenes to CD4+ T cells. JCI Insight. 2022 DEC 13.
|
|
|
To submit any announcements, funding opportunities, events, or other important items to this newsletter, please make use of the newsletter submission form that is linked below.
Please direct any questions that you may have to our Marketing and Communications Coordinator, Sarah Christie at sjchristie@health.ucsd.edu
|
|
|
|
Want to be highlighted in the MCC weekly newsletter or on the MCC website?
We want to know and share in all of our successes at MCC. To that end, we have created a pipeline for our members to share recent publications, awards, new appointments, and research highlights that you would like to see in our MCC weekly newsletter or on the MCC website. Please provide us with the data that we need to showcase your great work by completing the Member Survey linked below.
We sincerely thank you in advance for your time!
|
|
|
Moores Cancer Center (MCC) is not only one of only 52 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention of cancer in San Diego County. The 360 MCC member scientists and clinicians hail from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and cancer-risk research, MCC investigators address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. Holding Comprehensive status since 2001, MCC was founded in 1977 by John Mendelsohn and received its NCI designation in 1978.
|
|
|
Department of Research Administration
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails. View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to schristie@ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|